Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROCHLOROTHIAZIDE & TRIAMTERENE

All products: not a benefit

Other products in the same Health Canada class (C03EA) — coverage varies; not interchangeable

  • Amiloride + hydrochlorothiazide (Moduret): general benefit, Not a benefit
  • Hydrochlorothiazide + spironolactone (Aldactazide-25): general benefit, Not a benefit

Dyazide · DIN 01919547 · 25mg & 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-03-05 — choose a marketed DIN from the same-category list.Discontinued 2001-03-05 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-03-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-03-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dyazide · DIN 01919547 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 1996-10-01 Daily cost (source): $0.0608 Health Canada: Cancelled post market since 2001-03-05 · brand DYAZIDE TAB · ATC C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS · form Tablet · route Oral · ingredients TRIAMTERENE 50 MG, HYDROCHLOROTHIAZIDE 25 MG · company Dmvet inc · schedule Prescription
Check this DIN again · Health Canada product record

Dyazide: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15906 · Verify on the e-Formulary ↗ (DIN 01919547)

Source record
DIN 01919547: Dyazide Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 402800025; group id 563; item number 1506; lccId None; manufacturer id SMJ Source form: Tab; strength: 25mg & 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01919547 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15906
Interchangeable products
Apo-Triazide · DIN 00441775 · $0.0608 Teva-Triamterene/HCTZ · DIN 00532657 · $0.0608
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2001-03-05 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-TRIAZIDE (Triamterene and Hydrochlorothiazide) is indicated in the maintenance therapy of: • Patients with edema associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome; also in steroid induced edema and idiopathic edema. • Patients with mild to moderate hypertension in those patients who have developed hypokalemia while on thiazide-like diuretics alone, and in those patients in whom potassium depletion is considered especially dangerous (e.g. digitalized patients). Medical opinion is not unanimous regarding the incidence and/or clinical significance of hypokalemia occurring among hypertensive patients treated with thiazide-like diuretics alone, and concerning the use of potassium-sparing combinations as routine therapy in hypertension. Fixed-dose combination drugs are not indicated for initial therapy. Patients should be titrated on the individual drugs. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. If during maintenance therapy dosage adjustment is necessary it is advisable to us… https://pdf.hres.ca/dpd_pm/00085869.PDF PM date: 2026-08-25 Source product: APO-TRIAZIDE; DIN 00441775; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Dyazide: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026